The tumor targeting ability of C/M@Alb NCs was also validated by ex vivo near-infrared fluorescence (NIRF) imaging of the excised tumors and major organs, after a single-dose (3.5 mg kg−1) injection of Ce6-conjugated C/M@Alb NCs into tumor-bearing mice. This evidence concerns the gene ALB and neoplasm.